Validation of a saliva test using methylated microRNAs for head and neck cancer recurrence
使用甲基化 microRNA 进行唾液测试验证头颈癌复发情况
基本信息
- 批准号:10281743
- 负责人:
- 金额:$ 27.33万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-21 至 2023-08-31
- 项目状态:已结题
- 来源:
- 关键词:AlgorithmsApplications GrantsBiologicalBiological AssayClinicalClinical Practice GuidelineClinical ResearchDetectionDevelopmentDistantEarly DiagnosisFollow-Up StudiesFutureGoalsHead and Neck CancerHead and Neck NeoplasmsHead and Neck Squamous Cell CarcinomaHead and neck structureHealth Care CostsIncidenceInstitutionInterventionLaboratoriesLarynxLeadMagnetic Resonance ImagingMalignant NeoplasmsMedicalMedical ImagingMethodsMicroRNAsNational Comprehensive Cancer NetworkNatureObservational StudyOperative Surgical ProceduresOral cavityOutcomePET/CT scanPatientsPerformancePeriodicityPharyngeal structurePhasePositron-Emission TomographyPrevalenceProspective StudiesPublishingRadiation exposureRadiation therapyRecurrenceReproducibilityResearchResourcesRoentgen RaysSalivaScreening for cancerSpecificitySquamous cell carcinomaSystemTestingTimeTissue SampleTissuesTongueTumor BurdenTumor TissueUltrasonographyUniversitiesValidationWashingtonbasebiomarker developmentbiomarker panelcancer biomarkerscancer recurrenceclinical applicationclinical practiceclinical translationcohortcost effectivedetection methodexperimental studygenomic locusimprovedmeetingsmicroRNA biomarkerspatient populationpreclinical studyprediction algorithmprospectiverandom forestrural areasaliva analysissaliva samplesalivary assayscreeningsuccesstesting accesstool
项目摘要
PROJECT SUMMARY
The objective of this combined UH2/UH3 application is to develop a non-invasive, accurate, and cost-effective
saliva-based test for early detection of squamous cell carcinoma of the head and neck (SCCHN) recurrence.
SCCHN includes squamous cell carcinomas derived from oral cavity, tongue, pharynx and larynx. It is the 7th
most common cancer in US and worldwide by incidence, and the 3rd in US and 4th worldwide by 5-year
prevalence. SCCHN is a biologically aggressive cancer in which high rates of recurrence (local, locoregional or
distant) contribute significantly to poor patient survival. Current clinical practice methods for detection of
SCCHN recurrence are either subjective, invasive, hard to access, not able to detect recurrence in a timely
manner or expensive. There is an unmet medical need for an objective, non-invasive, easy to access test that
is able to detect SCCHN recurrence in a timely and a cost-effective way. Our solution is “HNKlear”, a non-
invasive, saliva-based candidate test for early detection of SCCHN recurrence. HNKlear incorporates a 7-
methylated microRNA biomarker panel. The real-time nature of our test will provide more timely and precise
detection of SCCHN recurrence. In our published proof of concept studies, HNKlear demonstrated 92%
sensitivity and 98% specificity in ~300 SCCHN and control tissue samples and 85% sensitivity and 95% in
~200 SCCHN and control saliva samples using continuous variables, which supports the clinical translation of
the test. We propose a combined UH2/UH3 application for the clinical translation of HNKlear. In the UH2
phase, we will analytically validate the test and algorithm in a pre-clinical study and in a new patient cohort.
Success of this phase will let us lock down the test and cut-off when the milestone is met. We will then conduct
a clinical study in the UH3 phase to demonstrate the clinical validity of HNKlear for SCCHN recurrence in an
observational clinical follow-up study incorporating HNKlear into current clinical practice. Success of this phase
will generate robust evidence of the clinical validity of HNKlear for early detection of SCCHN recurrence, and
will further enable clinical application of HNKlear as a Laboratory Developed Test.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shi-Long Lu其他文献
Shi-Long Lu的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shi-Long Lu', 18)}}的其他基金
Validation of a saliva test using methylated microRNAs for head and neck cancer recurrence
使用甲基化 microRNA 进行唾液测试验证头颈癌复发情况
- 批准号:
10929597 - 财政年份:2021
- 资助金额:
$ 27.33万 - 项目类别:
Validation of a saliva test using methylated microRNAs for head and neck cancer recurrence
使用甲基化 microRNA 进行唾液测试验证头颈癌复发情况
- 批准号:
10491773 - 财政年份:2021
- 资助金额:
$ 27.33万 - 项目类别:
The Role of PI3K Pathway in Head and Neck Cancer Invasion and Metastasis
PI3K通路在头颈癌侵袭和转移中的作用
- 批准号:
8843734 - 财政年份:2011
- 资助金额:
$ 27.33万 - 项目类别:
The Role of PI3K Pathway in Head and Neck Cancer Invasion and Metastasis
PI3K通路在头颈癌侵袭和转移中的作用
- 批准号:
8086949 - 财政年份:2011
- 资助金额:
$ 27.33万 - 项目类别:
The Role of PI3K Pathway in Head and Neck Cancer Invasion and Metastasis
PI3K通路在头颈癌侵袭和转移中的作用
- 批准号:
8231322 - 财政年份:2011
- 资助金额:
$ 27.33万 - 项目类别:
The Role of PI3K Pathway in Head and Neck Cancer Invasion and Metastasis
PI3K通路在头颈癌侵袭和转移中的作用
- 批准号:
8402544 - 财政年份:2011
- 资助金额:
$ 27.33万 - 项目类别:
The Role of PI3K Pathway in Head and Neck Cancer Invasion and Metastasis
PI3K通路在头颈癌侵袭和转移中的作用
- 批准号:
8596809 - 财政年份:2011
- 资助金额:
$ 27.33万 - 项目类别: